Tags

Type your tag names separated by a space and hit enter

Glargine versus NPH insulin: efficacy in comparison with insulin aspart in a basal bolus regimen in type 1 diabetes--the glargine and aspart study (GLASS) a randomised cross-over study.
Diabetes Res Clin Pract. 2007 Aug; 77(2):215-22.DR

Abstract

The aim of the study was to compare the efficacy of insulin glargine and aspart with NPH insulin and aspart in a basal bolus regimen in type 1 diabetes. In this 36-week randomised open-label two-period cross-over trial, subjects received 16 weeks' treatment with either once-daily insulin glargine or twice-daily NPH insulin after 4-week run-in. Primary outcome was HbA1c and secondary outcomes were fasting plasma glucose (FPG), weight change, incidence of hypoglycaemia, effect on lipid profile and patient satisfaction. Sixty patients with type 1 diabetes were recruited (33 male, mean age 42.7 years, mean HbA1c 8.53%) with 53 completing the study. At completion, HbA1c was lower with glargine and aspart than with NPH and aspart (8.07% versus 8.26%, difference -0.19 [95% CI 0.37-0.01]%, p=0.04). FPG was significantly different between glargine and NPH (p=0.002), with mean FPG on glargine 3mmol/L lower than on NPH at the end of the study. There were no differences in hypoglycaemia rate (p=0.63), weight (p=0.45) or lipid profile (p=0.18). Patient satisfaction was greater with glargine (DTSQ, p=0.001). Three patients discontinued as they wished to remain on glargine. We suggest that glargine combined with aspart is an effective basal bolus regimen in type 1 diabetes.

Authors+Show Affiliations

Department of Diabetes, University Hospitals of Leicester, Leicester, UK. sudesna.chatterjee@uhl-tr.nhs.ukNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17141354

Citation

Chatterjee, S, et al. "Glargine Versus NPH Insulin: Efficacy in Comparison With Insulin Aspart in a Basal Bolus Regimen in Type 1 Diabetes--the Glargine and Aspart Study (GLASS) a Randomised Cross-over Study." Diabetes Research and Clinical Practice, vol. 77, no. 2, 2007, pp. 215-22.
Chatterjee S, Jarvis-Kay J, Rengarajan T, et al. Glargine versus NPH insulin: efficacy in comparison with insulin aspart in a basal bolus regimen in type 1 diabetes--the glargine and aspart study (GLASS) a randomised cross-over study. Diabetes Res Clin Pract. 2007;77(2):215-22.
Chatterjee, S., Jarvis-Kay, J., Rengarajan, T., Lawrence, I. G., McNally, P. G., & Davies, M. J. (2007). Glargine versus NPH insulin: efficacy in comparison with insulin aspart in a basal bolus regimen in type 1 diabetes--the glargine and aspart study (GLASS) a randomised cross-over study. Diabetes Research and Clinical Practice, 77(2), 215-22.
Chatterjee S, et al. Glargine Versus NPH Insulin: Efficacy in Comparison With Insulin Aspart in a Basal Bolus Regimen in Type 1 Diabetes--the Glargine and Aspart Study (GLASS) a Randomised Cross-over Study. Diabetes Res Clin Pract. 2007;77(2):215-22. PubMed PMID: 17141354.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Glargine versus NPH insulin: efficacy in comparison with insulin aspart in a basal bolus regimen in type 1 diabetes--the glargine and aspart study (GLASS) a randomised cross-over study. AU - Chatterjee,S, AU - Jarvis-Kay,J, AU - Rengarajan,T, AU - Lawrence,I G, AU - McNally,P G, AU - Davies,M J, Y1 - 2006/12/01/ PY - 2006/10/02/received PY - 2006/11/06/accepted PY - 2006/12/5/pubmed PY - 2007/8/8/medline PY - 2006/12/5/entrez SP - 215 EP - 22 JF - Diabetes research and clinical practice JO - Diabetes Res Clin Pract VL - 77 IS - 2 N2 - The aim of the study was to compare the efficacy of insulin glargine and aspart with NPH insulin and aspart in a basal bolus regimen in type 1 diabetes. In this 36-week randomised open-label two-period cross-over trial, subjects received 16 weeks' treatment with either once-daily insulin glargine or twice-daily NPH insulin after 4-week run-in. Primary outcome was HbA1c and secondary outcomes were fasting plasma glucose (FPG), weight change, incidence of hypoglycaemia, effect on lipid profile and patient satisfaction. Sixty patients with type 1 diabetes were recruited (33 male, mean age 42.7 years, mean HbA1c 8.53%) with 53 completing the study. At completion, HbA1c was lower with glargine and aspart than with NPH and aspart (8.07% versus 8.26%, difference -0.19 [95% CI 0.37-0.01]%, p=0.04). FPG was significantly different between glargine and NPH (p=0.002), with mean FPG on glargine 3mmol/L lower than on NPH at the end of the study. There were no differences in hypoglycaemia rate (p=0.63), weight (p=0.45) or lipid profile (p=0.18). Patient satisfaction was greater with glargine (DTSQ, p=0.001). Three patients discontinued as they wished to remain on glargine. We suggest that glargine combined with aspart is an effective basal bolus regimen in type 1 diabetes. SN - 0168-8227 UR - https://www.unboundmedicine.com/medline/citation/17141354/Glargine_versus_NPH_insulin:_efficacy_in_comparison_with_insulin_aspart_in_a_basal_bolus_regimen_in_type_1_diabetes__the_glargine_and_aspart_study__GLASS__a_randomised_cross_over_study_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0168-8227(06)00500-6 DB - PRIME DP - Unbound Medicine ER -